KRAS; A Key Oncogenic Driver and Novel Investigational Target in NSCLC

Join us for a session on KRAS. The program will feature expert speakers reviewing the evolving NSCLC landscape and emerging biomarkers, raise awareness that KRAS G12C is the most prevalent emerging molecular target in NSCLC, define patient and tumor characteristics, and discuss clinical guideline recommendations for molecular testing at diagnosis of NSCLC.FLASCO Members Participate for FREE!